DOI . ORG {}

Analyzed Page
Matching Content Categories
CMS
Monthly Traffic Estimate
How Does Doi.org Make Money
Keywords
Topics
Questions
Schema
External Links
Analytics And Tracking
Libraries
Hosting Providers
CDN Services

We began analyzing https://link.springer.com/article/10.1007/BF03029778, but it redirected us to https://link.springer.com/article/10.1007/BF03029778. The analysis below is for the second page.

Title[redir]:
Torsades de pointes: Prevention and therapy | Cardiovascular Drugs and Therapy
Description:
Torsades de pointes (TdP) is a life-threatening ventricular tachycardia that occurs in the setting of a prolonged QT interval and is most frequently related to administration of antiarrhythmic drugs. Patients with organic heart disease, with low serum electrolyte levels, with a previous episode of TdP and with bradycardia or baseline QT prolongation may be at increased risk of developing TdP. After initiation of a QT prolonging therapy, the dosage should be modified if the QT interval reaches 560–600 ms. Cessation of medication and immediate hospitalization are indicated in the presence of lightheadedness, syncope, or increased frequency and complexity of ventricular premature beats. The conventional therapy of TdP with isoproterenol or cardiac pacing, although usually effective, has certain disadvantages. Isoproterenol is contraindicated in patients with hypertension or ischemic heart disease, whereas institution of cardiac pacing requires skilled personnel and fluoroscopy. Recently, infusion of magnesium sulfate has been shown to abolish TdP both in the clinical and experimental setting. Compared with conventional therapy, magnesium sulfate has the advantage of safety and simplicity of its administration. In doubtful cases, if does not aggravate a ventricular tachycardia that is not TdP, as may occur with isoproterenol. This advantage and the prompt effectiveness of the drug in four clinical series, including 31 patients, support the use of magnesium sulfate as the first line of therapy for TdP.

Matching Content Categories {📚}

Health & Fitness
Education
Science

Content Management System {📝}

What CMS is doi.org built with?

Custom-built

No common CMS systems were detected on Doi.org, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of doi.org audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Doi.org Make Money? {💸}

We don’t know how the website earns money.

Not every website is profit-driven; some are created to spread information or serve as an online presence. Websites can be made for many reasons. This could be one of them. Doi.org might be cashing in, but we can't detect the method they're using.

Keywords {🔍}

google, scholar, pubmed, cas, article, ventricular, pointes, cardiol, magnesium, torsade, torsades, therapy, tzivoni, heart, keren, patients, tachycardia, clinical, tdp, sulfate, cardiac, privacy, cookies, content, drugs, access, fibrillation, quinidine, med, data, publish, search, prolongation, syncope, pacing, treatment, atypical, features, coll, long, polymorphous, induced, effect, information, log, journal, research, andre, dan, interval,

Topics {✒️}

open-access database amiodarone-induced ventricular fibrillation month download article/chapter life-threatening ventricular tachycardia disopyramide-induced ventricular fibrillation torsades de pointes long-short initiating sequence torsade de pointes �torsade de pointes” polymorphous ventricular tachycardia article cardiovascular drugs atypical ventricular tachycardia full article pdf ventricular tachyarrhythmias induced polymorphopus ventricular tachycardia paroxysmal ventricular fibrillation privacy choices/manage cookies related subjects la tachycardie ventriculaire arrhythmia previously induced article keren baseline qt prolongation ventricular premature beats chronic atrial arrhythmias intractable ventricular tachyarrhythmias unusual ventricular arrhythmia ventricular tachycardia check access instant access prolonged qt interval long qt syndrome long qt syndromes intravenous magnesium sulphate ventricular arrhythmias european economic area frequently related vander ark cr delayed repolarization syndromes torsioni di punta organophosphorus insecticide poisining canine purkinje fibers stimulation rate bikur cholim hospital conditions privacy policy ventricular fibrillation qt prolonging therapy accepting optional cookies article log qt prolongation main content log

Questions {❓}

Drug-Induced QT Prolongation and Torsades de Pointes: An All-Exclusive Relationship or Time for an Amicable Separation?
Good, bad or indifferent?

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Torsades de pointes: Prevention and therapy
         description:Torsades de pointes (TdP) is a life-threatening ventricular tachycardia that occurs in the setting of a prolonged QT interval and is most frequently related to administration of antiarrhythmic drugs. Patients with organic heart disease, with low serum electrolyte levels, with a previous episode of TdP and with bradycardia or baseline QT prolongation may be at increased risk of developing TdP. After initiation of a QT prolonging therapy, the dosage should be modified if the QT interval reaches 560–600 ms. Cessation of medication and immediate hospitalization are indicated in the presence of lightheadedness, syncope, or increased frequency and complexity of ventricular premature beats. The conventional therapy of TdP with isoproterenol or cardiac pacing, although usually effective, has certain disadvantages. Isoproterenol is contraindicated in patients with hypertension or ischemic heart disease, whereas institution of cardiac pacing requires skilled personnel and fluoroscopy. Recently, infusion of magnesium sulfate has been shown to abolish TdP both in the clinical and experimental setting. Compared with conventional therapy, magnesium sulfate has the advantage of safety and simplicity of its administration. In doubtful cases, if does not aggravate a ventricular tachycardia that is not TdP, as may occur with isoproterenol. This advantage and the prompt effectiveness of the drug in four clinical series, including 31 patients, support the use of magnesium sulfate as the first line of therapy for TdP.
         datePublished:
         dateModified:
         pageStart:509
         pageEnd:513
         sameAs:https://doi.org/10.1007/BF03029778
         keywords:
            torsades de pointes
            ventricular tachycardia
            sudden death
            magnesium
            Cardiology
         image:
         isPartOf:
            name:Cardiovascular Drugs and Therapy
            issn:
               1573-7241
               0920-3206
            volumeNumber:5
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer Netherlands
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Andre Keren
               affiliation:
                     name:Bikur Cholim Hospital
                     address:
                        name:The Heiden Department of Cardiology, Bikur Cholim Hospital, Jerusalem, Israel
                        type:PostalAddress
                     type:Organization
                     name:Hebrew University Hadassah Medical School
                     address:
                        name:Hebrew University Hadassah Medical School, Jerusalem, Israel
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Dan Tzivoni
               affiliation:
                     name:Bikur Cholim Hospital
                     address:
                        name:The Heiden Department of Cardiology, Bikur Cholim Hospital, Jerusalem, Israel
                        type:PostalAddress
                     type:Organization
                     name:Hebrew University Hadassah Medical School
                     address:
                        name:Hebrew University Hadassah Medical School, Jerusalem, Israel
                        type:PostalAddress
                     type:Organization
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Torsades de pointes: Prevention and therapy
      description:Torsades de pointes (TdP) is a life-threatening ventricular tachycardia that occurs in the setting of a prolonged QT interval and is most frequently related to administration of antiarrhythmic drugs. Patients with organic heart disease, with low serum electrolyte levels, with a previous episode of TdP and with bradycardia or baseline QT prolongation may be at increased risk of developing TdP. After initiation of a QT prolonging therapy, the dosage should be modified if the QT interval reaches 560–600 ms. Cessation of medication and immediate hospitalization are indicated in the presence of lightheadedness, syncope, or increased frequency and complexity of ventricular premature beats. The conventional therapy of TdP with isoproterenol or cardiac pacing, although usually effective, has certain disadvantages. Isoproterenol is contraindicated in patients with hypertension or ischemic heart disease, whereas institution of cardiac pacing requires skilled personnel and fluoroscopy. Recently, infusion of magnesium sulfate has been shown to abolish TdP both in the clinical and experimental setting. Compared with conventional therapy, magnesium sulfate has the advantage of safety and simplicity of its administration. In doubtful cases, if does not aggravate a ventricular tachycardia that is not TdP, as may occur with isoproterenol. This advantage and the prompt effectiveness of the drug in four clinical series, including 31 patients, support the use of magnesium sulfate as the first line of therapy for TdP.
      datePublished:
      dateModified:
      pageStart:509
      pageEnd:513
      sameAs:https://doi.org/10.1007/BF03029778
      keywords:
         torsades de pointes
         ventricular tachycardia
         sudden death
         magnesium
         Cardiology
      image:
      isPartOf:
         name:Cardiovascular Drugs and Therapy
         issn:
            1573-7241
            0920-3206
         volumeNumber:5
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer Netherlands
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Andre Keren
            affiliation:
                  name:Bikur Cholim Hospital
                  address:
                     name:The Heiden Department of Cardiology, Bikur Cholim Hospital, Jerusalem, Israel
                     type:PostalAddress
                  type:Organization
                  name:Hebrew University Hadassah Medical School
                  address:
                     name:Hebrew University Hadassah Medical School, Jerusalem, Israel
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Dan Tzivoni
            affiliation:
                  name:Bikur Cholim Hospital
                  address:
                     name:The Heiden Department of Cardiology, Bikur Cholim Hospital, Jerusalem, Israel
                     type:PostalAddress
                  type:Organization
                  name:Hebrew University Hadassah Medical School
                  address:
                     name:Hebrew University Hadassah Medical School, Jerusalem, Israel
                     type:PostalAddress
                  type:Organization
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Cardiovascular Drugs and Therapy
      issn:
         1573-7241
         0920-3206
      volumeNumber:5
Organization:
      name:Springer Netherlands
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Bikur Cholim Hospital
      address:
         name:The Heiden Department of Cardiology, Bikur Cholim Hospital, Jerusalem, Israel
         type:PostalAddress
      name:Hebrew University Hadassah Medical School
      address:
         name:Hebrew University Hadassah Medical School, Jerusalem, Israel
         type:PostalAddress
      name:Bikur Cholim Hospital
      address:
         name:The Heiden Department of Cardiology, Bikur Cholim Hospital, Jerusalem, Israel
         type:PostalAddress
      name:Hebrew University Hadassah Medical School
      address:
         name:Hebrew University Hadassah Medical School, Jerusalem, Israel
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Andre Keren
      affiliation:
            name:Bikur Cholim Hospital
            address:
               name:The Heiden Department of Cardiology, Bikur Cholim Hospital, Jerusalem, Israel
               type:PostalAddress
            type:Organization
            name:Hebrew University Hadassah Medical School
            address:
               name:Hebrew University Hadassah Medical School, Jerusalem, Israel
               type:PostalAddress
            type:Organization
      name:Dan Tzivoni
      affiliation:
            name:Bikur Cholim Hospital
            address:
               name:The Heiden Department of Cardiology, Bikur Cholim Hospital, Jerusalem, Israel
               type:PostalAddress
            type:Organization
            name:Hebrew University Hadassah Medical School
            address:
               name:Hebrew University Hadassah Medical School, Jerusalem, Israel
               type:PostalAddress
            type:Organization
PostalAddress:
      name:The Heiden Department of Cardiology, Bikur Cholim Hospital, Jerusalem, Israel
      name:Hebrew University Hadassah Medical School, Jerusalem, Israel
      name:The Heiden Department of Cardiology, Bikur Cholim Hospital, Jerusalem, Israel
      name:Hebrew University Hadassah Medical School, Jerusalem, Israel
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(200)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

Emails and Hosting {✉️}

Mail Servers:

mx.zoho.eu
mx2.zoho.eu
mx3.zoho.eu

Name Servers:

josh.ns.cloudflare.com
zita.ns.cloudflare.com

CDN Services {📦}

Crossref

4.79s.